Plus Therapeutics Reports Second Quarter 2020 Financial and Business Results (GlobeNewswire) - Aug 10, 2020 - "In the second half of Fiscal Year 2020, the Company intends to focus on a number of additional business objectives and potential milestones: Report preliminary RNL™ data from the ReSPECT Phase I dose finding trial in recurrent glioblastoma; Finalize RNL Phase 2/pivotal trial plan in recurrent glioblastoma; Seek RNL Orphan Drug Designation decisions from regulatory agencies; Complete evaluations of additional external and internal drug development candidates; Initiate IND-enabling RNL studies for additional indications; Explore partnership opportunities for RNL, DocePLUS and DoxoPLUS assets."
Clinical • IND • Orphan drug • P1 data • Brain Cancer • Glioblastoma • Oncology
|